Goldman Sachs Group Inc Uro Gen Pharma Ltd. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 317,522 shares of URGN stock, worth $3.36 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
317,522
Previous 315,957
0.5%
Holding current value
$3.36 Million
Previous $4.01 Million
15.73%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding URGN
# of Institutions
132Shares Held
36MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$40.1 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$39.6 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$24.4 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$23.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$23.1 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $241M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...